Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX
Vertex Pharmaceuticals (VRTX) Stock Price & Analysis
5,168 Followers
VRTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$320.01 - $448.40
Previous Close$397.48
Volume604.57K
Average Volume (3M)1.19M
Market Cap
$102.67B
Enterprise Value$92.18B
Total Cash (Recent Filing)$11.22B
Total Debt (Recent Filing)$724.70M
Price to Earnings (P/E)28.6
Beta0.58
Next Earnings
May 06, 2024EPS Estimate
$4.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)13.89
Shares Outstanding258,307,816
10 Day Avg. Volume998,170
30 Day Avg. Volume1,194,470
Standard Deviation0.08
R-Squared0.06
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)6.56
Price to Sales (P/S)10.40
Price to Cash Flow (P/CF)109.40
P/FCF Ratio187.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.34
Enterprise Value/Gross Profit10.71
Enterprise Value/Ebitda27.24
Forecast
1Y Price Target
$456.11Price Target Upside15.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering27
Vertex Pharmaceuticals News
PremiumStock Analysis & Ideas
CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
Bulls Say, Bears Say
Bulls Say
Acquisition SynergyThe recent acquisition of Alpine Immune Sciences adds to Vertex’s nephrology portfolio with promising data, potentially transforming treatment options and strengthening their market position.
Product PipelinePipeline developments, including pain assets and a diabetes cell therapy drug-device combo, are showing progress in product diversification.
Strategic CollaborationsPartnership with TreeFrog signals ongoing progress with differentiated, insulin-producing pancreatic islet cells for VRTX’s T1D programs, enhancing the company's commitment to innovation.
Bears Say
Competitive PositionVRTX shares trade at a significant premium to the peer average.
Drug Efficacy And SalesInitial sales of Casgevy are predicted to be slower, with significant revenue not expected until the second half of the year.
R&D SetbacksStudy of VX-880 is on pause due to two deaths deemed unrelated to the treatment, but the pause may impact investor sentiment.
---
Ownership Overview
1.07% Insiders
52.29% Mutual Funds
24.85% Other Institutional Investors
21.79% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VRTX FAQ
What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest stock price was $320.01 and its highest was $448.40 in the past 12 months.
What is Vertex Pharmaceuticals’s market cap?
Currently, no data Available
When is Vertex Pharmaceuticals’s upcoming earnings report date?
Vertex Pharmaceuticals’s upcoming earnings report date is May 06, 2024 which is 3 days ago.
How were Vertex Pharmaceuticals’s earnings last quarter?
Vertex Pharmaceuticals released its earnings results on Feb 05, 2024. The company reported $4.2 earnings per share for the quarter, beating the consensus estimate of $4.067 by $0.133.
Is Vertex Pharmaceuticals overvalued?
According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay dividends.
What is Vertex Pharmaceuticals’s EPS estimate?
Vertex Pharmaceuticals’s EPS estimate is $4.08.
How many shares outstanding does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 258,307,830 shares outstanding.
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Vertex Pharmaceuticals reported an EPS of $4.2 in its last earnings report, beating expectations of $4.067. Following the earnings report the stock price went down -2.975%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
Among the largest hedge funds holding Vertex Pharmaceuticals’s share is Bridgewater Associates, LP. It holds Vertex Pharmaceuticals’s shares valued at 54M.
---
Vertex Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$456.11 (15.12% Upside)
$456.11 (15.12% Upside)
Blogger Sentiment
Bullish
VRTX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 2.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.27%
12-Months-Change
Fundamentals
Return on Equity
22.99%
Trailing 12-Months
Asset Growth
27.19%
Trailing 12-Months
Company Description
Vertex Pharmaceuticals
Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
---
VRTX Company Deck
---
VRTX Earnings Call
Q4 2024
0:00 / 0:00
---
VRTX Revenue Breakdown
90.63% TRIKAFTA/KAFTRIO
4.82% KALYDECO
3.30% ORKAMBI
1.25% SYMDEKO/SYMKEVI
---
VRTX Stock 12 Month Forecast
Average Price Target
$456.11
▲(15.12% Upside)
Technical Analysis
Best Analysts Covering VRTX
1 Year
1 Year Success Rate
20/20 ratings generated profit
1 Year Average Return
+32.44%
reiterated a sell rating 28 days ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +32.44% per trade.
---